文献速递乳腺技术与安全MRPET

侵袭性乳腺癌新辅助化疗患者中99mTc-司他比分子乳腺成像与乳腺MRI的比较

Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy.
PubMed 文献 · AJR Am J Roentgenol · 2019-06-05

前瞻性比较乳腺MRI与分子乳腺成像(MBI)在新辅助化疗(NAC)前后测量侵袭性乳腺癌大小的准确性。NAC后MRI敏感度82.8%、特异度69.4%,MBI敏感度58.9%、特异度82.4%;两种方法预测乳腺病理完全缓解的准确性均不足以替代组织学诊断。

要点

  • NAC后MRI敏感度82.8%、特异度69.4%,MBI敏感度58.9%、特异度82.4%。
  • NAC前MRI与MBI最长径相差在1.0 cm内者占72.3%,NAC后占70.1%。
  • NAC后MRI与病理肿瘤大小相差在1 cm内者占58.7%,MBI占59.6%。

核心结论

  • NAC前乳腺MRI与MBI所示病变范围相似;MBI可能作为有乳腺MRI禁忌证患者的替代检查。NAC后两种方法预测乳腺病理完全缓解的准确性均不足以替代组织学诊断评估残留侵袭性疾病,且NAC后与病理评估对比界定残留病变范围均有限。

研究设计与样本

  • 前瞻性研究,纳入侵袭性乳腺癌≥1.5 cm的女性,比较NAC前后MRI与MBI最长径;MBI采用双探测器碲锌镉系统,注射6.5 mCi(240 MBq)99mTc-司他比后进行;以病理检查为参考标准评估残留病变(侵袭性疾病或导管原位癌)的准确性。

关键影像表现/征象

  • NAC前MRI与MBI最长径相差在1.0 cm内者占72.3%,NAC后占70.1%。
  • NAC后影像最长径与病理肿瘤大小相差在1 cm内者,乳腺MRI为58.7%,MBI为59.6%。

诊断标准与关键数值

  • NAC后MRI敏感度82.8%、特异度69.4%、阳性预测值81.4%、阴性预测值71.4%。
  • NAC后MBI敏感度58.9%、特异度82.4%、阳性预测值84.6%、阴性预测值54.9%。
  • 90例NAC后同时接受MRI与MBI;56例有侵袭性残留病变者中,MRI阴性10例(17.9%),MBI阴性23例(41.1%)。
  • 34例乳腺病理完全缓解者中,MRI有强化10例(29.4%),MBI有摄取6例(17.6%)。

临床应用与阅片要点

  • NAC前MRI与MBI所示病变范围相似,MBI可能作为有乳腺MRI禁忌证患者的替代检查。
  • NAC后MRI与MBI预测乳腺病理完全缓解的准确性均不足以替代组织学诊断评估残留侵袭性疾病。
  • NAC后MRI与MBI与病理评估对比界定残留病变范围均有限。

局限性

  • NAC后乳腺MRI与MBI与病理评估对比界定残留病变范围均有限。
  • NAC后两种方法预测乳腺病理完全缓解的准确性均不足以替代组织学诊断评估残留侵袭性疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this study is to prospectively compare the size of invasive breast cancer before and after neoadjuvant chemotherapy (NAC) at breast MRI and molecular breast imaging (MBI) and to assess the accuracy of post-NAC MBI and MRI relative to pathologic analysis. SUBJECTS AND METHODS. Women with invasive breast cancer greater than or equal to 1.5 cm were enrolled to compare the longest dimension before and after NAC at MRI and MBI. MBI was performed on a dual-detector cadmium zinc telluride system after administration of 6.5 mCi (240 MBq) 99mTc-sestamibi. The accuracy of MRI and MBI in assessing residual disease (invasive disease or ductal carcinoma in situ) was determined relative to pathologic examination. RESULTS. The longest dimension at MRI was within 1.0 cm of that at MBI in 72.3% of cases before NAC and 70.1% of cases after NAC. The difference between the longest dimension at imaging after NAC and pathologic tumor size was within 1 cm for 58.7% of breast MRI cases and 59.6% of MBI cases. Ninety patients underwent both MRI and MBI after NAC. In the 56 patients with invasive residual disease, 10 (17.9%) cases were negative at MRI and 23 (41.1%) cases were negative at MBI. In the 34 patients with breast pathologic complete response, there was enhancement in 10 cases (29.4%) at MRI and uptake in six cases (17.6%) at MBI. Sensitivity, specificity, positive predictive value, and negative predictive value after NAC were 82.8%, 69.4%, 81.4%, and 71.4%, respectively, for MRI and 58.9%, 82.4%, 84.6%, and 54.9%, respectively, for MBI. CONCLUSION. Breast MRI and MBI showed similar disease extent before NAC. MBI may be an alternative to breast MRI in patients with a contraindication to breast MRI. Neither modality showed sufficient accuracy after NAC in predicting breast pathologic complete response to obviate tissue diagnosis to assess for residual invasive disease. Defining the extent of residual disease compared with pathologic evaluation was also limited after NAC for both breast MRI and MBI.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Hunt KN, Conners AL, Goetz MP, et al. Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy. AJR Am J Roentgenol. 2019. PMID: 31166752. doi:10.2214/AJR.18.20628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。